Hmmm. I am noticing that ex-US trials are not reporting race... Should this be a required element for @ASCO presentations?
Study design of MITO-23
MITO23 endpoints:
Primary: Overall Survival
Secondary: Progression Free Survival

Very interesting that OS was the primary endpoint I think...
Nice CONSORT diagram showing who was included in what analysis:
Hmmm. I am noticing that ex-US trials are not reporting race... Should this be a required element for @ASCO presentations for #ASCO23 and beyond?
Prof. Lorusso: Trabectidin failed to demonstrate an increase in overall survial (same in progression free survival).
Finally, the appropriate way to use "fail" in the context of trial reporting.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Don S. Dizon MD 🇬🇺

Don S. Dizon MD 🇬🇺 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @drdonsdizon

Jun 6
Dr Veneziani up presenting the PESCO trial
Maveropepimut-S targets Survivin protein
Prior studies showed safety
Read 6 tweets
Jun 6
Study volunteers: 35% had platinum-refractory disease and 6% had primary platinum-refractory disease. 12% had a BRCA mutation
Continuous relacorilant treatment seemed more toxic to me: worse events of neuropathy and fatigue.
Read 5 tweets
Jun 6
This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22
This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22
Retrospective study suggests bevacizumab + chemo improved survival in people with ovarian clear cell carcinoma. Hypothesis generating for sure.
This study was a larger retrospective in Japan before and after Bev was approved.
Read 9 tweets
Jun 6
Next up #gyncsm #ASCO22 Ruxolitinib
Ruxolitinib = JACK 1/2 inhibitor. The IL-6/JAK/STAT3 implicated in the survival of cancer stem like cells. Inhibition of this axis may improve the activity of chemotherapy.
SO... "dispositioned to neoadjuvant chemotherapy" seems really weird to say. These volunteers were recommended to NACT.
Read 7 tweets
Jun 6
#gyncsm ATHENA-MONO volunteers
75% White, 22% Asian.
This will be a problem going forward. Volunteers on trials should represent the demographics of those who get the disease.
FWIW: Ref SEER (Cases per 100K persons)
ATHENA-MONO Progression free survival favors rucaparib over placebo in volunteers with HRD
Monk: Subgroup analyses all point towards benefit to rucaparib
Read 5 tweets
Jan 7
The Omicron surge has been truly devastating... for cancer centers. 🧵 1/9
Operating rooms are operating, but on a day by day basis as staff are sent elsewhere to cover. 2/9
I've found myself arguing with surgical colleagues but why "my patient" should go to the OR before "their patient" 3/9
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(